Email ID
Password
Forgotten your password?
Sign me in automatically next time
Advanced Search
Home
Companies
Patients
Investigators
Trials & Research
Regulatory
Therapeutics
Therapeutics
LATEST NEWS
PPD and VirtualScopics expand strategic alliance for medical imaging services
27 January 2012
PPD and VirtualScopics have expanded their one-year strategic alliance in clinical and medical imaging services across multiple therapeutic areas to now include oncology, central nervous system, cardiovascular, general medicine and medical devices. The companies deliver integrated and customised ...
Quintiles enters development partnership for Intarcia's diabetes therapy
14 December 2011
Quintiles and Intarcia Therapeutics have signed an agreement whereby Quintiles will become a financial and strategic partner for the global clinical development of Intarcia's ITCA 650 (DUROS continuous subcutaneous delivery of exenatide). Depending on successful development and approval, ITCA 650 ...
Debiopharm inks deal with INC Research
26 July 2011
The CRO INC Research has formed a strategic partnership with Swiss biopharmaceutical company Debiopharm , which will see the CRO manage a clinical study for Debio 0932, while both have agreed a framework for INC's collaboration on future trials. INC Research will be firstly working on a trial for ...
Quintiles makes further investment to accelerate Prana's Alzheimer's drug
04 July 2011
In its second deal in as many weeks, Quintiles has made a significant investment to progress the clinical development of a biotech compound. The CRO has invested $1 million into the Australian biotech Prana Biotechnology , to fund the accelerated development and Phase II clinical trials of its ...
>> More Latest News...
FEATURES
Interest persists in new treatments for HCV
01 February 2012
Last year saw the first in a new class of product for treating hepatitis C infections reach the market. Vertex Pharmaceuticals’ Incivek (telaprevir) and Merck & Co’s Victrelis (boceprevir) are protease inhibitors (to be more accurate, they inhibit viral NS3 serine protease, an enzyme required for ...
Compliance issues beset hypertension market
24 November 2011
On the face of it, one would think that patients prescribed antihypertensive medication would be happy to take it. After all, the benefits of treating asymptomatic hypertension – specifically, a reduced risk of heart attack and stroke – are well established. But studies have repeatedly shown that ...
The surge for safety in MS treatment
19 September 2011
There are many promising candidates under development for multiple sclerosis, with a range of different mechanisms of action. Ian Schofield looks at what the pipeline may hold in the way of future treatments for this disabling and difficult-to-treat disease. Severe pain, bowel dysfunction, muscle ...
Breathing new life into asthma research
09 June 2011
Although existing treatments are highly effective, the asthma sector continues to attract a great deal of interest, not least because new types of treatment are being developed. Peter Charlish looks at some of the products under investigation, focusing on those in early development. Asthma is an ...
>> More Features...
PEOPLE
Exco InTouch hires CTO
Exco InTouch , a provider of mobile patient engagement and communication solutions has hired Madhav Vattikuti as Chief Technology Officer (CTO). Vattikuti’s role will see him use his significant technology expertise and background to strengthen delivery and development of Exco InTouch’s market ...
Chiltern adds therapeutic experts to team
The CRO Chiltern International has hired Drs Marcelo Piccirillo and Carlo Lanza to its medical teams. Dr Piccirillo will serve as senior clinical research physician with special emphasis in developing the gastroenterology therapeutic area. He has 20 years experience in the medical and clinical ...
Henauer joins i3 as head of resourcing
PharmaNet/i3 , inVentiv Health’s clinical segment, has hired Dr Stephan Henauer as executive director, i3 Pharma Resourcing. In this role, Dr Henauer will provide leadership for PharmaNet/i3’s staffing business in central, eastern and northern Europe. Prior to joining PharmaNet/i3, Dr Henauer was ...
>> More People...
COMMENTARY
Deals to drive innovation for the next three billion
Deals such as ICON’s recent acquisition of BeijingWits Medical Consulting not only reflect the opportunity presented by emerging growth markets but also the need for local knowledge to conduct business effectively and tailor new product development to local market needs. We expect more deals to ...
Prepare for the regulatory revolution
Every medicine has associated side effects, or adverse drug reactions (ADRs). The European Impact Assessment Report on Pharmacovigilance (PV) estimated that approximately 5% of all hospital admissions are due to ADRs and that ADRs are the fifth most common cause of hospital death, accounting for an ...
CROs: focus on therapeutic areas for project gains
Lifestyle, living standards and longevity will all play their part in the disease profile of the future global population. Aligned with these factors is the shifting market for pharmaceuticals, an increasing proportion of profits will come from outside of the US and Europe as the developing world ...
Navigating the sea of data protection law in European clinical research
In Europe, there is a common set of rules that regulate the collection, use, and sharing of personal data. These include strict protection of sensitive data such as health data. However, individual European countries have interpreted and implemented the rules on the use of health data in clinical ...
Lean strategies for R&D partnership transformation
Lean methods for transformation, believes Deloitte 's Julian Remnant , could form a foundation for multi-company collaborations that might define the next generation of industry partnerships. In my April column, I recognised the benefits R&D organisations have realised from the first generation of ...
Delivery partners will have opportunity to shape sponsor IT strategy
Information technology investments in R&D will begin to target the ‘value analytics’ agenda, believes Deloitte 's Julian Remnant , and to do so, he suggests sponsors will increasingly draw on their delivery partners to shape operational IT strategy. The last ten years has seen industry-wide IT ...
>> More Commentary...
About Us
Getting Started
Subscribe
FREE Trial
Advertise
Awards
White Papers
EVENTS
Partnerships in Clinical Trials
04 March 2012
The Marriott World Center, Orlando, Florida
